Johnson & Johnson (JNJ) Asset Utilization Ratio (2009 - 2026)
Johnson & Johnson (JNJ) posted Asset Utilization Ratio of 0.49 for Q2 2026, up 1.16% sequentially from 0.48 in Q1 2026, and up 4.05% YoY from 0.47 in Q2 2025.
Johnson & Johnson (JNJ) Asset Utilization Ratio (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Asset Utilization Ratio for 18 years, with the latest figure at 0.49 in Q2 2026.
- Quarterly Asset Utilization Ratio rose 4.05% year-over-year to 0.49 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.49 (up 4.05% YoY) and the FY2025 annual result came in at 0.5, down 2.8% from the prior year.
- Asset Utilization Ratio advanced to 0.49 in Q2 2026 per JNJ's latest filing, from 0.48 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.51 in Q4 2023 and troughed at 0.42 in Q2 2023.
- A 5-year average of 0.48 and a median of 0.48 in 2025 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2023 and 2024: Asset Utilization Ratio dropped 14.21% in 2023, then climbed 19.32% in 2024.
- Over 5 years, Asset Utilization Ratio stood at 0.47 in 2022, then advanced by 8.01% to 0.51 in 2023, then fell by 2.91% to 0.5 in 2024, then decreased by 3.05% to 0.48 in 2025, then increased by 1.4% to 0.49 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.49, 0.48, and 0.48 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 0.49 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 0.47 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 0.52 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 0.53 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 0.40 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 0.58 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 0.31 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 0.64 |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 0.36 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 0.49 |
| Mar 29, 2026 | 0.48 |
| Dec 28, 2025 | 0.48 |
| Sep 28, 2025 | 0.48 |
| Jun 29, 2025 | 0.47 |
| Mar 30, 2025 | 0.48 |
| Dec 29, 2024 | 0.50 |
| Sep 29, 2024 | 0.49 |
| Jun 30, 2024 | 0.49 |
| Mar 31, 2024 | 0.50 |
| Dec 31, 2023 | 0.51 |
| Oct 1, 2023 | 0.47 |
| Jul 2, 2023 | 0.42 |
| Apr 2, 2023 | 0.42 |
| Jan 1, 2023 | 0.44 |
| Oct 2, 2022 | 0.47 |
| Jul 3, 2022 | 0.49 |
| Apr 3, 2022 | 0.49 |
| Oct 3, 2021 | 0.51 |
| Jul 4, 2021 | 0.51 |